Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05105152 | PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML | PHASE1 | RECRUITING | 18 | — | — | Nov 29, 2021 | Jan 31, 2041 | Dec 23, 2025 | 1 | United States |
The type, frequency, severity, and duration of adverse events will be summarized
Measure of the number of successfully manufactured SC-DARIC33 products
| Arm | Type | Description |
|---|---|---|
| DARIC-33 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| SC-DARIC33 | BIOLOGICAL | Infusion with SC-DARIC33 followed by intermittent oral rapamycin administration |
Inclusion Criteria: 1. Subject age ≤ 30 years. The first three enrolled subjects must be ≥ 18 years of age. 2. AML that expresses CD33 by flow cytometry and meets one of the below definitions: 1. For subjects who have previously received an allogeneic HCT, any evidence of AML re-emergence post ...